Healthcare Industry News: HSMN NewsFeed
News Release - February 13, 2017
Prollenium Medical Technologies Inc. Acquires Rights to Distribute Selphyl(R)AURORA, ON, Feb. 13, 2017 --(Healthcare Sales & Marketing Network)-- Prollenium Medical Technologies Inc., a Canadian company based out of Aurora, Ontario, has acquired the rights to distribute the Selphyl Platelet-rich Fibrin System.
The Selphyl System is designed for the safe and rapid preparation of Platelet-rich Fibrin Matrix (PRFM) from a small sample of blood at the patient point of care. This superior technology has treated over 150k patients worldwide.
"We are thrilled to be able to add Selphyl to our Canadian sales portfolio. Selphyl has been a trailblazer for regenerative medicine in the aesthetic industry and when combined with our best-in-class hyaluronic acid product family Revanesse, we have a synergy that gives better outcomes for both the physician and patient," says CEO Ario Khoshbin of Prollenium Medical Technologies.
"As we increase our global business, it is very important to select distribution partners that share the same vision in providing best-in-class technologies for physicians and their patients. We are honored and delighted to enter into a long-term collaboration with Prollenium Medical Technologies at this exciting time," stated Dr. Sanjay Batra, CEO of Factor Medical/Selphyl.
The Selphyl System is available exclusively through Prollenium across Canada. All orders should be placed with the Prollenium Customer Service department using the following methods:
- Phone at 1-866-353-3015
- Fax at 1-866-876-6716
- Email at firstname.lastname@example.org
Prollenium Medical Technologies Inc., founded in 2002, is dedicated to the research, design, manufacture and distribution of implantable polymers in the medical aesthetic industry. The company is committed to providing innovative products worldwide that are safe and viable. Flagship product lines include RevanesseŽ Hyaluronic Acid Dermal Fillers and AlyriaŽ Skin Optimizing System.
Source: Prollenium Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.